Skip navigation
sponsored by 

Epilepsy drugs risky for some Asian patients

FDA: Certain medications for the condition can cause serious skin reactions

Health care videos
Free clinic helps uninsured in New Orleans
  Nov. 16: The New Orleans convention center was transformed into a one-day free health clinic, with hundreds of volunteers treating more than a thousand people. The clinic was funded in part by msnbc’s Keith Olbermann. Dr. Nancy Snyderman talks with the clinic’s director Dr. Corey Hebert.

INTERACTIVE
Dose of reality
Dose of reality
Do health care reform headlines leave you saying “huh?” Visit msnbc.com's guide to health reform and send us claims you'd like fact-checked.
updated 5:21 p.m. ET Nov. 24, 2008

WASHINGTON - Treatment with certain epilepsy drugs may expose some Asian patients to serious skin reactions, federal health officials warned Monday.

The Food and Drug Administration said it is investigating whether medications like Dilantin, Phenytek and Cerebyx, which are used to control epileptic seizures, can lead to severe skin blisters and bleeding for some Asian patients.

Patients who test positive for a gene known as HLA-B.1502 appear to be at increased risk of developing the skin problems, preliminary data indicate. About 10 percent to 15 percent of patients from parts of China, Thailand, Malaysia, Indonesia and the Philippines may carry the gene, as do 2 percent to 4 percent of South Asians, including Indians.

Story continues below ↓
advertisement | your ad here

The FDA urged doctors to monitor patients closely, but said there is not enough information yet to recommend genetic testing. In most cases, patients who develop the skin problems do so in the first few months after starting to take the medications.

Because of the problem with skin reactions, the FDA last year recommended genetic testing for Asian patients taking another epilepsy drug, carbamazepine, sold under several brand names including Tegretol and Carbatrol. Doctors should also avoid Dilantin and the other medications for patients who have already tested positive for the gene, the FDA said.

© 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Resource guide